scholarly journals Sensorineural Hearing Loss of Suspected Autoimmune Etiology: Two Cases of Cogan’s Syndrome

2021 ◽  
Vol 64 (12) ◽  
pp. 943-948
Author(s):  
Jungmin Ahn ◽  
Brian Kim ◽  
Kyoung Rai Cho ◽  
Young-Soo Chang

Cogan’s syndrome is a rare inflammatory disease characterized by non-syphilitic keratitis and vestibulo-auditory symptoms including hearing loss, tinnitus, and vertigo. Although its precise pathogenesis is not known, Cogan’s syndrome is generally considered an autoimmune disease. This hypothesis is supported by the frequently successful remission of hearing loss after steroid administration and the association with other autoimmune disorders such as rheumatoid arthritis. Medical treatment of Cogan’s syndrome depends on disease severity and on how extensive the disease is. The involvement of inner ear pathology requires systemic corticosteroid therapy. In cases of treatment failure or the need for a corticosteroid-sparing effect, other immunosuppressive drugs can be used. We experienced two patients with typical Cogan’s syndrome, presenting bilateral progressive sensorineural hearing loss and dizziness with ocular involvement, which we have successfully treated with systemic steroid administration and immunosuppressive therapy.

2018 ◽  
Vol 30 ◽  
pp. 50-53
Author(s):  
José Luis Treviño González ◽  
German A. Soto-Galindo ◽  
Rafael Moreno Sales ◽  
Josefina A. Morales Del Ángel

2016 ◽  
Vol 2016 ◽  
pp. 1-4 ◽  
Author(s):  
Daniel R. Bunker ◽  
Leslie Dubin Kerr

Importance. Rituximab was not effective in ameliorating the hearing loss in a patient with atypical Cogan’s syndrome.Observations. We report the case of a patient who developed acute bilateral uveitis and sensorineural hearing loss. A diagnosis of atypical Cogan’s syndrome was made. The patient’s hearing loss did not improve despite high dose steroids and azathioprine. Rituximab was administered given a recent report of its efficacy in a patient with refractory disease; however, our patient’s hearing loss did not improve.Conclusion. Hearing loss in Cogan’s syndrome is difficult to treat. Though rituximab was ineffective in our case, earlier administration in the disease course could be effective for future patients.


2005 ◽  
Vol 132 (4) ◽  
pp. 527-531 ◽  
Author(s):  
Brian D. Herr ◽  
Sam J. Marzo

OBJECTIVE: Patients with sudden sensorineural hearing loss (SSHL) can benefit from systemic steroid therapy. Unfortunately, some patients are not candidates for steroid therapy due to concern over possible complications. Furthermore, not all patients will benefit from steroid administration. This study evaluates the potential benefits and safety of treating patients with SSHL refractory to oral steroids with intratympanic steroid therapy. METHODS: A retrospective case review was performed on all patients who presented with sudden sensorineural hearing loss refractory to oral steroid therapy during the past year. Seventeen patients were identified. All patients underwent intratympanic steroid administration, via MicroWick placement and/or round window catheter placement. RESULTS: Nine patients with sudden sensorineural hearing loss showed an improvement with intratympanic steroid therapy, consisting of MicroWick placement with dexamethasone drop (Decadron) administration for 1–2 weeks and/or round window catheter placement with steroid perfusion. Only one of the patients presenting with hearing loss present for greater than 8 weeks benefited from intratympanic therapy. Complications were few and included tympanic membrane perforation, chronic otitis media, dysequilibrium, and dysguesia. CONCLUSIONS: Intratympanic steroid therapy can be beneficial in treating patients with sudden sensorineural hearing loss refractory to oral steroid use. EBM rating: C.


2004 ◽  
Vol 47 (3) ◽  
pp. 175-180
Author(s):  
Tsukasa Ito ◽  
Tomoo Watanabe ◽  
Masaru Aoyagi

2021 ◽  
Vol 124 (1) ◽  
pp. 35-42
Author(s):  
Yoshihiko Hiraga ◽  
Koichiro Wasano ◽  
Taiji Kawasaki ◽  
Nobuyoshi Tsuzuki ◽  
Sosuke Sahara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document